Iopamiro (Iopamidol)

Iopamidol contains iodine atoms that strongly absorb X‑ray photons. When injected into the vascular system, the iodine increases the radiodensity of blood and surrounding structures, creating a contrast difference that imaging equipment can detect. This heightened attenuation produces detailed images of anatomical features, facilitating diagnosis and interventional guidance.

The dose of Iopamiro is determined by the prescribing physician based on the specific imaging study, patient weight, renal function and the required level of contrast enhancement. The healthcare professional calculates the appropriate volume and concentration, and administers it under controlled conditions during the procedure.

The safety of Iopamiro during pregnancy or lactation has not been definitively established. It should only be used if the potential diagnostic benefit outweighs any possible risk to the fetus or infant. Clinicians are advised to consider alternative imaging modalities and consult current guidelines before administration to pregnant or nursing patients.

To place an order, submit an enquiry on the Iopamiro product page at gnhindia.com, specifying the required quantity and providing institutional credentials. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional documentation, and then responds with pricing, availability, shipping details (including any cold‑chain requirements) and necessary import paperwork.

Iopamiro (iopamidol) is a low‑osmolality, nonionic iodinated contrast medium, offering a favorable safety profile compared with older high‑osmolality agents that are more likely to cause discomfort and adverse reactions. Compared with other low‑osmolality agents, it provides comparable image quality while reducing the incidence of warmth sensations and mild allergic responses, making it a widely accepted choice for many imaging procedures.

Iopamiro should be stored at ambient temperature, protected from direct sunlight, moisture and freezing. Keep the vial in its original packaging until use, and avoid shaking the solution. Before administration, inspect the container for particulate matter or discoloration, and discard any product that appears compromised or is beyond its expiration date.

Iopamiro is supplied as a sterile solution for injection and is administered intravenously or intra‑arterially by a qualified healthcare professional. The injection is typically performed using a power injector or manual bolus, depending on the imaging protocol. The volume and rate of administration are tailored to the specific procedure and patient characteristics, ensuring optimal contrast enhancement while minimizing risk.

The most serious risks include severe allergic reactions such as anaphylaxis, acute kidney injury especially in patients with pre‑existing renal impairment, and hemodynamic instability like profound hypotension. Rarely, contrast‑induced neurotoxicity or cardiac arrhythmias may occur. Prompt recognition and appropriate emergency management are essential, and patients at high risk should be closely monitored during and after administration.

Iopamiro is contraindicated in patients with a known hypersensitivity to iopamidol or any iodinated contrast media, as well as those with a history of severe anaphylactic reactions to similar agents. It should also be avoided in individuals with uncontrolled hyperthyroidism, severe renal insufficiency, or those who are pregnant unless the diagnostic benefit clearly outweighs potential risks. Clinicians must assess each patient’s medical history before deciding to use the product.